ADMA Biologics ADMA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $509.86M+11.0% | $510.17M+19.6% | $488.56M+27.6% | $474.17M+43.6% | $459.38M+62.2% | ||
| $197.45M-9.4% | $217.41M+5.1% | $221.28M+13.2% | $222.86M+25.2% | $217.84M+26.9% | ||
| $312.42M+29.3% | $292.77M+33.3% | $267.28M+42.7% | $251.32M+65.0% | $241.54M+117% | ||
| 61.3%+8.7pp | 57.4%+5.9pp | 54.7%+5.8pp | 53%+6.9pp | 52.6%+13.2pp | ||
| $6.53M+198% | $4.76M+163% | $3.78M+102% | $2.66M+29.6% | $2.19M-24.4% | ||
| $94.24M+14.1% | $91.58M+23.6% | $91.39M+37.7% | $88.17M+41.1% | $82.56M+37.3% | ||
| —— | $3.1M+14.8% | $3M+5.3% | $2.9M-3.3% | $2.8M-11.1% | ||
| $97.58M+9.0% | $101.32M+25.8% | $100.27M+38.5% | $95.68M+40.0% | $89.5M+33.0% | ||
| $214.84M+41.3% | $191.44M+37.7% | $167.01M+45.4% | $155.64M+85.4% | $152.04M+243% | ||
| 42.1%+9.0pp | 37.5%+4.9pp | 34.2%+4.2pp | 32.8%+7.4pp | 33.1%+17.5pp | ||
| $7.24M-40.4% | $7.11M-49.0% | $8.36M-51.6% | $10.19M-49.5% | $12.14M-46.5% | ||
| -$8.5M+24.6% | -$8.79M+33.8% | -$11.24M+72.9% | -$10.63M+76.3% | -$11.28M+76.2% | ||
| $206.33M+46.6% | $182.66M+45.3% | $155.78M+112% | $145.01M+270% | $140.76M+4,715% | ||
| $40.98M+162% | $35.73M+150% | -$53.67M-1,127% | -$63.92M-1,558% | -$66.01M-11,194% | ||
| $165.35M-20.0% | $146.93M-25.7% | $209.45M+207% | $208.93M+501% | $206.77M+5,773% | ||
| 32.4%-12.6pp | 28.8%-17.6pp | 42.9%+25.1pp | 44.1%+33.5pp | 45%+46.3pp | ||
| $0.68-20.0% | $0.60-26.8% | $0.86+207% | $0.86+514% | $0.85+4,350% | ||
| $222.64M+39.4% | $199.34M+35.9% | $174.91M+53.9% | $163.44M+106% | $159.74M+250% | ||
| 43.7%+8.9pp | 39.1%+4.7pp | 35.8%+6.1pp | 34.5%+10.4pp | 34.8%+18.7pp | ||
| $214.84M+41.3% | $191.44M+37.7% | $167.01M+57.5% | $155.64M+117% | $152.04M+300% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ADMA Biologics's revenue?
- ADMA Biologics (ADMA) generated $509.9M in revenue over the trailing twelve months, up 11.0% year over year.
- Is ADMA Biologics profitable?
- ADMA Biologics reported $165.4M in net income over the trailing twelve months, a 32.4% net margin.
- What are ADMA Biologics's profit margins?
- Gross margin is 61.3% and operating margin is 42.1%, with a 32.4% net margin.
- What is ADMA Biologics's earnings per share?
- ADMA Biologics's diluted EPS over the trailing twelve months is $0.68.
- Where does ADMA Biologics's income statement data come from?
- Every line is extracted from ADMA Biologics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
